Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-5625
- Development stage
- Phase 1
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MT-5625 is a plant-based, non-replicating virus-like particle (VLP) vaccine that was under development by Mitsubishi Tanabe Pharma. It is designed as an immunostimulant and has been investigated for use as a rotavirus vaccine. The vaccine is administered intramuscularly and does not contain any live or replicating viral material, instead using VLP technology to stimulate an immune response against rotavirus infection.
- Other names
- MT 5625MT5625MT-5625
02
Targets
VP4 (Rotavirus VP4)VP7 (Rotavirus VP7)
Beyond the preview
Go deeper on MT-5625.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-5625.